Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

NCT04730999 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Etoposide
DRUG: Carboplatin
DRUG: Bevacizumab
DRUG: Atezolizumab

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica

Collaborators

[object Object]
[object Object]
[object Object]